f ribociclib with alfentanil is necessary, as the systemic exposure of alfentanil may be increased resulting in an increase in alfentanil-related adverse reactions. Monitor patients frequently for respiratory depression and sedation; adjust the dose of alfentanil if necessary. Ribociclib is a moderate CYP3A4 inhibitor and alfentanil is a CYP3A4 substrate with a narrow therapeutic window.
Alfuzosin: (Major) Avoid coadministration of ribociclib with alfuzosin due to an increased risk for QT prolongation. Systemic exposure of alfuzosin, a CYP3A4 substrate, may also be increased by ribociclib, a moderate CYP3A4 inhibitor, resulting in an increase in alfuzosin-related adverse reactions. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Based on electrophysiology studies performed by the manufacturer, alfuzosin may also prolong the QT interval in a dose-dependent manner. Concomitant use may increase the risk for QT prolongation.
Aliskiren: (Moderate) Use caution if coadministration of ribociclib with aliskiren is necessary, as the systemic exposure of aliskiren may be increased resulting in an increase in aliskiren-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and aliskiren is a CYP3A4 substrate.
Aliskiren; Amlodipine: (Moderate) Use caution if coadministration of ribociclib with aliskiren is necessary, as the systemic exposure of aliskiren may be increased resulting in an increase in aliskiren-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and aliskiren is a CYP3A4 substrate. (Moderate) Use caution if coadministration of ribociclib with amlodipine is necessary, as the systemic exposure of amlodipine may be increased resulting in an increase in treatment-related adverse reactions including hypotension and edema. Exposure to ribociclib may also increase, increasing ribociclib-related adverse reactions (e.g., neutropenia, QT prolongation). Ribociclib is a moderate CYP3A4 inhibitor and is extensively metabolized by CYP3A4. Amlodipine is a CYP3A4 substrate and a weak CYP3A4 inhibitor.
Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ: (Moderate) Use caution if coadministration of ribociclib with aliskiren is necessary, as the systemic exposure of aliskiren may be increased resulting in an increase in aliskiren-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and aliskiren is a CYP3A4 substrate. (Moderate) Use caution if coadministration of ribociclib with amlodipine is necessary, as the systemic exposure of amlodipine may be increased resulting in an increase in treatment-related adverse reactions including hypotension and edema. Exposure to ribociclib may also increase, increasing ribociclib-related adverse reactions (e.g., neutropenia, QT prolongation). Ribociclib is a moderate CYP3A4 inhibitor and is extensively metabolized by CYP3A4. Amlodipine is a CYP3A4 substrate and a weak CYP3A4 inhibitor.
Aliskiren; Hydrochlorothiazide, HCTZ: (Moderate) Use caution if coadministration of ribociclib with aliskiren is necessary, as the systemic exposure of aliskiren may be increased resulting in an increase in aliskiren-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and aliskiren is a CYP3A4 substrate.
Aliskiren; Valsartan: (Moderate) Use caution if coadministration of ribociclib with aliskiren is necessary, as the systemic exposure of aliskiren may be increased resulting in an increase in |
